BioNTech’s €16.8 Billion Cash Pile Meets Its Biggest Test at ASCO as Cancer Pipeline Takes Center Stage

The German biotech enters a pivotal week in Chicago armed with a formidable treasury and a slate of late-stage oncology readouts that will test whether its post-COVID future can finally take shape. BioNTech’s stock closed at €82.35 on Friday, gaining 2.68% on the day and 3.58% for the holiday?shortened week, but the bounce remains tentative. The shares still sit 4.45% below the 200?day moving average of €86.18 and roughly 19% off their 52?week high, underscoring the market’s wait?and?see posture.

The company’s financial strength, however, is beyond doubt. At the end of March, BioNTech held €16.763 billion in cash, cash equivalents and securities — equivalent to roughly $19.6 billion. Of that total, €9.939 billion was in cash and equivalents, with €4.697 billion in short?term investments and €2.127 billion in longer?term holdings. That war chest gives management ample runway to fund expensive clinical trials while the COVID vaccine business continues its steady decline.

The vaccine segment received a minor regulatory fillip last week when the European Commission approved an updated formulation for children aged six months to four years. The revised regimen switches from three doses to two and standardises the dose at 10 micrograms for everyone under 11. It keeps the franchise operationally relevant, but BioNTech has already warned that 2026 COVID vaccine sales will be lower than 2025, driven by falling demand in Europe and the United States.

Those headwinds were visible in the latest quarterly accounts. First?quarter revenue came in at €118.1 million ($138.0 million), while the net loss widened to €531.9 million ($622.3 million), or €2.10 per diluted share. Research and development spending alone reached €651.6 million ($746 million). Despite the red ink, management reaffirmed its 2026 revenue target of €2.0?billion to €2.3?billion and its full?year 2025 outlook of $2.3?billion to $2.6?billion.

Should investors sell immediately? Or is it worth buying BioNTech?

The spotlight this week is firmly on the oncology pipeline. At the ASCO annual meeting, BioNTech is presenting data across multiple programmes, with the most closely watched coming from pumitamig, its lead bispecific antibody. An interim analysis from the dose?optimisation portion of the Phase?2/3 ROSETTA Lung?02 trial showed encouraging anti?tumour activity in first?line non?small cell lung cancer, covering both squamous and non?squamous histologies and all PD?L1 expression levels. Those results are feeding into a registrational Phase?3 study that pits pumitamig plus chemotherapy head?to?head against Merck’s Keytruda, the current standard of care.

Alongside pumitamig, BioNTech is showcasing gotistobart in heavily pre?treated, platinum?resistant ovarian cancer. Phase?2 data point to durable anti?tumour responses, clinically meaningful overall survival and a manageable safety profile. The CTLA?4?targeting antibody is strategically important because BioNTech intends to combine it with other modalities, including antibody?drug conjugates, as part of a broader platform approach.

The company now expects to have 15 active Phase?3 studies by year?end, with seven late?stage oncology data packages planned for 2025. A US marketing application for trastuzumab pamirtecan is also in the works. On the cost side, BioNTech is restructuring to preserve cash: production exits at sites in Idar?Oberstein, Marburg, Singapore and several CureVac locations will affect roughly 1,860 positions and are expected to generate annual savings of about €584.9 million ($665 million) by 2029.

BioNTech at a turning point? This analysis reveals what investors need to know now.

Analysts remain broadly constructive, even if the stock’s recent performance has been lacklustre. The consensus of 17 analysts points to an average price target of $125.45, well above current levels. UBS upgraded the shares from “Neutral” to “Buy” on May?27, lifting its target to $135 from $117, citing growing confidence in the oncology pipeline and its market potential. Yet the range of views is wide: Canaccord Genuity trimmed its target to $158 but stays bullish, while Leerink is more cautious at $94.

Technically, the stock has reclaimed its 50?day moving average of €81.06, trading 1.59% above it, but that is not enough to signal a durable trend change. Until the 200?day line is decisively breached, the recovery remains vulnerable. The ASCO presentations, which run through June?2, represent the next potential catalyst. Convincing data on pumitamig and gotistobart could narrow the discount between BioNTech’s valuation and its clinical ambition — but without clear registrational evidence, the stock may continue to drift in a holding pattern.

Ad

BioNTech Stock: New Analysis - 30 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69447221 |